Printer Friendly

Effect of L-carnitine on acetyl-CoA content and activity of blood platelets in healthy and diabetic persons.

Vascular complications in diabetes mellitus develop as a result of several disturbances in lipoprotein metabolism, increased protein glycation, free radical production, and chronic inflammation (1, 2). Endothelial cell damage leads to decreased production of antiaggregating and vasodilating substances. Hyperglycemia itself may also trigger primary disturbances in platelet activity by the activation and excessive production of lipid proaggregatory compounds (2). Therefore, pharmacologic or biochemical interventions that reduce synthesis of lipid mediators of aggregation could prevent the development of diabetic angiopathy (1).

L-Carnitine is a metabolite involved in indirect transport of cytoplasmic long-chain acyl-CoA through the mitochondrial membrane. In the outer mitochondrial membrane, carnitine acyl-CoA transferase I (EC catalyzes reactions in which L-carnitine forms acylcarnitine intermediates. These intermediates are converted back to acyl-CoA on the inner mitochondrial membrane in reactions driven by acyl carnitine translocase and carnitine acyl-transferase II (EC Fatty acids supplied to the mitochondrial matrix are subsequently used in the beta-oxidation cycle (3). Some of the acetyl-CoA groups formed in mitochondria by pyruvate dehydrogenase (PDH; [3] EC reactions and/or in the betaChair oxidation cycle are transported to the cytoplasm, where they serve in several synthetic pathways as precursors for acetyl groups (3). In insulin-dependent tissues of omnivorous animals, the indirect ATP-citrate lyase (ACL; EC pathway was found to provide >70% of acetyl-CoA units for fatty acid synthesis (4, 5). In the brain, which in bulk is an insulin-independent organ (i.e., glucose transport to brain cells does not depend on insulin), the indirect ACL pathway and the direct, permeability transition-dependent transport of acetyl-CoA have been reported to provide acetyl-CoA for structural lipid synthesis in the cytoplasmic compartment of glial and noncholinergic neuronal cells (6, 7). Neurons contain insulinindependent GLUT3 and GLUT1 glucose transporters (8); therefore, streptozotocin-evoked diabetic hyperglycemia increases conversion of glucose to pyruvate and acetylCoA and stimulates acetylcholine synthesis in brain nerve terminals (7).

Like neurons, uptake of glucose into blood platelets is independent of insulin and is mediated through GLUT3 (9). It has been shown that diabetic hyperglycemia significantly increases the activity of key glucose and acetylCoA metabolism enzymes, including hexokinase, ACL, and PDH in platelets (10). On the other hand, there are no data on possible changes in the activity of acetyl-metabolizing enzymes such as carnitine acetyltransferase (, fatty acid synthetase, and citrate synthase (EC in platelets from persons with diabetes.

Our earlier data revealed that diabetes produces an almost 2-fold increase in acetyl-CoA content in platelets (10). This increase correlated with the degree of medium-term hyperglycemia assessed by the fructosamine concentration in diabetic plasma (11). We therefore postulated that increased provision of acetyl-CoA to the platelet cytoplasmic compartment through the ACL pathway activates synthesis of platelet proaggregatory factors such as polyunsaturated fatty acids in the course of this disease (10,11).

L-Carnitine derivatives have been reported to suppress platelet activity in healthy people (12,13). Oral application of propionyl-L-carnitine inhibited arachidonic acid turnover and reactive oxygen species production by the platelets (12). Another study demonstrated that inhibition of the synthesis of platelet-activating factor led to both in vivo and in vitro suppression of platelet activity by propionyl-L-carnitine. The authors suggested that the suppressed platelet activity was caused by intracellular hydrolysis of propionyl-L-carnitine to L-carnitine with subsequent depletion of acetyl-CoA as a result of acetyl-L-carnitine formation (13). This explanation, however, has not been confirmed by experimental findings. Other studies have demonstrated that inhibition of long-chain carnitine acyltransferase-1 by perhexiline, amiodarone, or 2-tetradecylglycidic acid inhibits platelet aggregation (14,15), suggesting that stimulation of acylcarnitine metabolism activates rather than inhibits platelet activity (15). However, there are no data on the effect of L-carnitine on the concentration and distribution of acetyl-CoA in platelets of healthy or diabetic individuals.

Our recent data demonstrated that excessive platelet activity in diabetes may also be linked to increased protein glycation and acetyl-CoA content (10,11). In addition, L-carnitine was found to increase the acetyl-CoA concentration and cholinergic activity in the brain (16). Thus, data demonstrating the suppression of platelet function by L-carnitine derivatives conflict with those demonstrating increased platelet and cholinergic neuron activity in hyperglycemic states (6,11-13,16). The aim of this study, therefore, was to investigate whether L-carnitine changes the amounts of acetyl-CoA in blood platelets and, if so, how it would affect basic indicators of platelet activity.

Materials and Methods


The experimental group consisted of patients with diabetes type 1 and 2 from the Diabetology Center of the Academic Medical Center, Medical University of Gdansk, attending the Central Clinical Laboratory for scheduled blood check-ups. The control group included healthy people coming to the Laboratory from the Occupational Health Unit for routine blood examination. Diabetic patients with albuminuria (albumin excretion in urine >0.03 g/day) or with evident macroangiopathy were not admitted to the study. None of the study participants had taken aspirin, phosphodiesterase inhibitors, calcium channel blockers, or nonsteroidal antunflammatory drugs for at least 2 weeks before blood drawing. Patients with type 2 diabetes were treated with a combination of diet and oral antidiabetic drugs. Additional 10-mL samples of blood were collected from each participant into morphology evacuated tubes containing 1 mg of tripotassium EDTA per 1 mL of blood. These samples were used for isolation of platelets for enzyme, acetyl-CoA, and aggregation assays. Remaining tests were performed with blood samples collected on physician request. The study protocol was approved by the Regional Bioethical Commission at the Medical University of Gdarisk (permission: TKE BN/ 350/97).


Reagents for enzyme and acetyl-CoA assays were supplied by Sigma Chemical Co. Thrombin was from BioMed, Coomassie Brilliant Blue G-250 was from Bio-Rad, and GPRP tetrapeptide was from Bachem AG. All other chemicals were of analytical grade. Venoject tubes used for blood collection were from Becton Dickinson.

Diagnostic assays for hemoglobin [A.sub.1c] (Hb [A.sub.1c]; cat. no. 1488414) and fructosamine (cat. no. 67246901) were from Roche. Determinations were performed on a Hitachi 917 biochemical analyzer (Roche). Plasma glucose was measured by a commercial assay on a Dimension RxL biochemical analyzer (bade Behring).


Blood cells and plasma were separated by centrifugation of whole blood at 1508 at 4[degrees]C for 15 min in a Jouan CR 3.12 centrifuge. The cells were washed twice with a volume of saline solution (9 g/L NaCl) equivalent to the plasma volume to increase platelet recovery (70%). The resulting platelet-rich plasma and subsequent washings were collected into a plastic tube and centrifuged at 5008 for 15 min to obtain platelet-poor plasma and a platelet pellet. The pellet was washed 3 times with a solution containing 140 mmol/L NaCl, 5 mmol/L sodium HEPES buffer (pH 7.4), 0.1 mmol/L EDTA, and 5 mmol/L glucose and then suspended in a small volume of the same solution to obtain a protein concentration of ~10 g/L. The platelet amount and yield of the separation procedure as well as contamination by other blood cells was assessed with the HMX automatic hematologic analyzer (Beckman-Coulter).


The activities of fatty acid synthetase, ketoglutarate dehydrogenase (EC, carnitine acetyltransferase, glucose-6-phosphate dehydrogenase (EC, and citrate synthase were assayed by methods described elsewhere (17-21). Immediately before the assays, platelet membranes were solubilized by the addition of Triton X-100 (final concentration, 0.2% by volume). Assays were performed at 37[degrees]C in an Ultrospec 3 spectrophotometer (Amersham-LKB).


The acetyl-CoA content was measured in freshly isolated platelets that were incubated in medium containing glucose to obtain a steady-state concentration under controlled conditions (10). Incubation medium (final volume, 1.0 mL) contained 20 mmol/L sodium HEPES buffer, 1.7 mmol/L sodium phosphate buffer (final pH of the medium, 7.4), 140 mmol/L NaCI, 5.0 mmol/L KCI, and 2.5 mmol/L glucose. For studies of acetyl-CoA metabolism in activated platelets, 0.1 U of thrombin was added along with 2.5 mmol/L GPRP peptide to prevent aggregation, as indicated (22). Changes in the composition of the basic medium are indicated in the text. Incubation was started by the addition of platelet suspension (1 mg of protein) and continued for 30 min at 37[degrees]C in polystyrene flat-bottomed vessels in a water bath with continuous shaking at 100 cycles/min. Incubation was terminated by transfer of 0.5-mL samples of the cell suspension to Eppendorf tubes placed in an ice bath followed by centrifugation for 1 min at 12 000g. The whole platelet pellet was deproteinized by addition of 0.08 mL of 5 mmol/L HCl and placement for 1 min in a boiling bath. After centrifugation, clear supernatants were taken for acetyl-CoA determinations by the cycling method using phosphotransacetylase and citrate synthase (23). In this method, addition of CoA-SH, palmitoyl-CoA, or myristoyl-CoA to the cycling medium in equivalent amounts with an acetyl-CoA calibrator did not interfere with its determination [Ref. (23) and our unpublished data].

To assess the intracellular distribution of acetyl-CoA, we mixed the remaining 0.5 mL of platelet suspension with an equal volume of ice-cold lysis solution containing 20 mmol/L Tris-HCl buffer (pH 7.4), 125 mmol/L KCl, 3 mmol/L EDTA, and 1.4 g/L digitonin, layered over a 0.5-mL mixture of silicon oils (AR-20 and AR-200, 1:2 by volume) in a 1.5-mL Eppendorf tube. After 30 s, the particulate fraction was separated by centrifugation for 1 min at 12 000g. The upper layer was collected for protein and lactate dehydrogenase assays. The silicon oil layer was discarded, and the pellet was deproteinized by the addition of 5 mmol/L HCl and incubation in a boiling bath for 1 min. It was then used for determination of particulate (mainly mitochondrial) acetyl-CoA. Cytoplasmic acetyl-CoA content was calculated by subtraction of mitochondrial acetyl-CoA content from that found in whole platelets. To check the reliability of the separation procedure, we occasionally determined the glutamate dehydrogenase and lactate dehydrogenase activities in the particulate and soluble fractions (10, 24).


Platelets were suspended in 0.3 mL of medium containing 140 mmol/L NaCI, 20 mmol/L sodium HEPES buffer (pH 7.4), and 2.5 mmol/L glucose to obtain a density of 200 to 300 x [10.sup.3]/[micro]L and preincubated for 5 min at 37[degrees]C in an APACT aggregometer (Labor) with simultaneous recording of spontaneous aggregation. Platelets were activated by the addition of 0.03 mL of thrombin (final concentration, 0.1 U/mL), and aggregation was recorded for 10 min at 37[degrees]C against a parallel blank without thrombin. Both samples were deproteinized by the addition of 0.05 mL of 200 g/L trichloroacetic acid; the mixture was shaken for 30 min at 4[degrees]C and centrifuged. Clear supernatants were taken for a malonyl dialdehyde (MDA) assay (25). Accumulation of MDA in thrombin-activated platelets was calculated by subtraction of the amount accumulated after 10 min in the activated sample from that present in the sample deproteinized at time zero.


Protein was quantified according to the method of Bradford (26) with bovine immunoglobulin as the calibrator.


The data distribution was tested by Kolmogorov-Smirnov test. A P value >0.1 was considered to be indicative of gaussian distribution. Differences between 2 experimental groups were tested by unpaired Student t-test. Results obtained on platelets isolated from the same person and exposed to different treatments were compared by use of the paired Student t-test. Correlations were assessed with the Pearson test. Calculations were performed with the GraphPad Prism 2.01 statistical package (GraphPad Software).



Persons with type 1 or type 2 diabetes were enrolled in the studies. Basic morphometric blood values, including platelet counts, volume, and protein content (Table 1) as well as erythrocyte and leukocyte counts and hemoglobin concentration (not shown), in the diabetic patients were similar to those for healthy individuals. In both diabetic groups, fasting plasma glucose, serum fructosamine, and blood Hb [A.sub.1c] concentrations were 110%, 52%, and 77% higher, respectively, than in healthy participants (Table 1). Serum cholesterol and triglyceride concentrations were significantly higher in the patients with type 2 diabetes than in the healthy participants and patients with type 1 diabetes. On average, the group with type 1 diabetes was younger and the group with type 2 diabetes was older than the healthy group (Table 1). Mean disease duration varied from 11.4 years for the group with type 1 diabetes to 14.5 years for the group with type 2 diabetes.

In our previous studies (10, 11), patients with type 2 diabetes, who were older and had higher cholesterol and triglyceride concentrations but similar hyperglycemia (glucose ~2000 mg/L) as patients with type 1 diabetes, had changes in acetyl-CoA concentrations and connected enzyme activities similar to those for patients with type 1 diabetes. These results indicate that disturbances in acetyl-CoA metabolism do not depend on the degree of dyslipidemia and age differences, but only on the degree of lasting hyperglycemia (10,11). Accordingly, the distribution of individual values for fructosamine (Table 1) and other markers of hyperglycemia (not shown) in blood were similar in persons with type 1 or type 2 diabetes. Therefore, in further studies, patients with either type 1 or type 2 diabetes were considered as 1 chronically hyperglycemic group.


Our previous studies demonstrated that diabetic hyperglycemia causes increased activity of several enzymes involved in glucose-derived acetyl group metabolism in platelets, such as hexokinase, PDH, and ACL (11). As shown in Table 2, diabetes caused increases in the activities of glucose-o-phosphate dehydrogenase (17%) carnitine acetyltransferase (21%), 2-oxoglutarate dehydrogenase (37%), and fatty acid synthetase (62%), but we found no significant changes in citrate synthase activity (Table 2).


Increasing glucose concentrations in the incubation medium caused a gradual increase in acetyl-CoA content in platelets from both groups. Maximum concentrations of acetyl-CoA were achieved at a glucose concentration of 2.5 mmol/L (Fig. 1). At this experimental point, the acetyl-CoA content in platelets from diabetic individuals was 60% higher than in the platelets from the healthy individuals (Fig. 1). In both diabetic and healthy persons, no significant changes in platelet acetyl-CoA concentrations occurred with further increases of the glucose concentration to 10 mmol/L.


To examine the role of glucose in provision of acetyl-CoA to the cytoplasmic compartment, intraplatelet distribution of this metabolite was assessed in platelets incubated in medium without and with 2.5 mmol/L glucose. In platelets obtained from both diabetic and healthy individuals, glucose caused no significant changes in mitochondrial acetyl-CoA concentration but caused a 2- to 3-fold increase in cytoplasmic acetyl-CoA (Fig. 2). On the other hand, for the group with diabetes, there was a 98% increase in mitochondrial acetyl-CoA but no significant changes in the cytoplasmic pool of this metabolite in platelets incubated in glucose-containing medium (Fig. 2).




In platelets from the diabetic group, incubated in medium containing 2.5 mmol/L glucose, L-carnitine (0.05-10.0 mmol/L) caused concentration-dependent increases in acetyl-CoA content. A half-maximal effect was observed at 1 mmol/L, whereas a maximal 53% increase was achieved at 2.5 mmol/L L-carnitine (Fig. 3). In platelets from the healthy group, the maximum increase in acetyl-CoA was lower (25%) at the same L-carnitine concentration (Fig. 3). An increase of L-carnitine to 10 mmol/L produced no change in acetyl-CoA content (Fig. 3). Therefore, in further experiments, a saturating concentration of L-carnitine (2.5 mmol/L) was used.


There was no difference between mean platelet acetyl-CoA content assessed in the absence or presence of L-carnitine in patients with type 1 or 2 diabetes (not shown). The distributions of individual acetyl-CoA measurements were also similar in both groups (not shown). Combined with the uniform distribution of plasma fructosamine concentrations (Table 1), these similarities justified consideration of both types of diabetes as a single experimental group.


For both the diabetic and healthy experimental groups, in the absence of glucose, 2.5 mmol/L L-carnitine caused no changes in acetyl-CoA content in the platelets (Table 3). For the healthy group, in platelets incubated with glucose, L-carnitine caused a 32% increase in acetyl-CoA content (Table 3). In platelets from the diabetic group, L-carnitine caused a much higher increase (69%) in total acetyl-CoA. Under these conditions, platelets from patients with diabetes contained 2-fold more acetyl-CoA than did platelets from the healthy group (Table 3).

L-carnitine produced no significant changes in intraplatelet distribution of acetyl-CoA in the healthy group (Fig. 4). On the other hand, in the diabetic group, L-carnitine increased cytoplasmic and mitochondrial acetyl-CoA by 100% and 26%, respectively (Fig. 4).

In platelets from the healthy group, incubated with or without L-carnitine, activation with thrombin did not change the acetyl-CoA content (Fig. 5). In contrast, in platelets from the diabetic group, incubated without or with L-carnitine, the addition of thrombin caused 24% and 51% decreases, respectively, in total acetyl-CoA content compared with the values for platelets from the healthy group (Fig. 5).


In the medium containing glucose, the spontaneous aggregation of platelets from the diabetic group was 60% higher than that of platelets from the healthy group (Table 4). L-carnitine increased spontaneous aggregation of platelets from the healthy and diabetic groups by 33% and 61%, respectively (Table 4). Under these conditions, platelet aggregation was 90% higher in samples from the diabetic group than in samples from the healthy participants. Compared with the platelets from the healthy group, thrombin-evoked aggregation of platelets from the diabetic group was 14% and 20% higher in L-carnitine-free and L-carnitine-supplemented medium, respectively (Table 4). L-carnitine alone caused a slight but significant 10% increase in thrombin-evoked aggregation of platelets from the diabetic group but not the healthy group.

ADP- and collagen-induced platelet aggregation rates were 16% and 12% higher, respectively, in the diabetic group than in the healthy group (Table 4). L-carnitine had no effect on these rates in platelets from the healthy group. On the other hand, L-carnitine increased ADP--and collagen-stimulated platelet aggregation in samples from the diabetic group by 10% and 14%, respectively (Table 4). In the presence of L-carnitine, both ADP--and collagen-evoked aggregation rates were ~26% higher in platelets from the diabetic group than in platelets from the healthy group (Table 4).




Under resting conditions, L-carnitine induced 25% and 61% increases in MDA production in platelets from the healthy and diabetic groups, respectively (Table 5). On the other hand, resting MDA production in platelets from the group with diabetes incubated without and with L-carnitine was 60% and 106% higher, respectively, than in platelets from the healthy group.

Stimulation with thrombin led to severalfold increases in MDA synthesis in both groups (Table 5). In the absence and presence of L-carnitine, thrombin-stimulated MDA synthesis was 73% and 104% higher, respectively, in platelets from the diabetic group than in platelets from the healthy group (Table 5). L-carnitine caused an 11% increase in MDA accumulation in platelets from the healthy group and a 31% increase in platelets from the diabetic group (Table 5).


To investigate the correlation between acetyl-CoA and platelet activity, indicators of platelet activity in individual participants were compared with the respective acetyl-CoA values (Table 6 and Fig. 6). In healthy persons, only 1 of 4 tested indicators of platelet activity displayed a moderately significant correlation (P <0.05) with platelet acetyl-CoA in either the absence or presence of L-carnitine (Table 6 and Fig. 6A). In platelets from diabetic participants incubated with L-carnitine, both spontaneous and thrombin-evoked MDA synthesis and aggregation displayed highly significant correlations (P <0.001) with platelet acetyl-CoA (Table 6 and Fig. 6B). In the absence of L-carnitine, 3 of 4 indicators of excessive platelet activity in samples from diabetic patients correlated significantly (P <0.01 and P <0.0001) with platelet acetyl-CoA content (Table 6).


The increased Hb [A.sub.1c] and fructosamine concentrations in the blood of diabetic patients in this study indicated that they remained chronically hyperglycemic within the 2- to 3-month and 2-week periods preceding the investigation, respectively (Table 1). The similar mean values and distributions of individual plasma values for fructosamine, blood glucose, Hb Al~, and platelet acetyl-CoA in patients with type 1 and 2 diabetes allowed for their assessment as a single hyperglycemic group (Table 1).

In platelets collected from diabetic patients for in vitro studies, increased fructosamine indicates that the platelets have been exposed to hyperglycemia at some time during their lifetime in circulation (Table 1). One may therefore postulate that increased activities of fatty acid synthetase, ketoglutarate, glucose-o-phosphate dehydrogenase, and carnitine acetyltransferase may be part of an adaptive response of megakaryocytes to the increased influx of glucose through the GLUT 3 glucose transporter (Table 2) (9). These data are also consistent with our previous findings demonstrating increases in hexokinase, PDH, and ATP-citrate lyase activities in platelets from patients with diabetes (11), allowing the conclusion that chronic hyperglycemia in megakaryocytes causes adaptive up-regulation of multiple key enzymes involved in the incorporation of acetyl units derived from glucose into fatty acids and, subsequently, to their biologically active signaling derivatives (25, 27). Increased glucose-6-phosphate dehydrogenase activity may suggest an increase in provision of NADPH for fatty acid synthesis in platelets of diabetic patients (Table 2). The increase in fatty acid synthetase activity in platelets from diabetic patients is consistent with this finding (Table 2), which could indicate the activation of fatty acid synthesis and use for energy production and peroxidation-dependent MDA synthesis in these platelets (Table 5) (28). In addition, the increases in ketoglutarate dehydrogenase (Table 2) and PDH (10) activity in platelets from diabetic patients indicates that energy production was also activated under these conditions.


Glucose-derived pyruvate from the mitochondrial PDH reaction is a main source of acetyl-CoA in platelets (29). Therefore, the increase in total acetyl-CoA content in platelets from diabetic patients might be attributable to increased metabolic flow of glucose through the glycolytic cycle to pyruvate and activation of its decarboxylation by PDH in mitochondria (Fig. 2 and Table 3) (10,11). This assumption is supported by the finding that a diabetes-evoked increase of acetyl-CoA in platelets was confined to their mitochondrial compartment (Fig. 2). Thus, mitochondria would be a primary site of excessive acetyl-CoA accumulation in disease-affected platelets (Fig. 2 and Table 3). On the other hand, the glucose-induced increase of the acetyl-CoA concentration in platelet cytoplasm indicates that this metabolite was efficiently transported from mitochondria to the cytoplasm in both healthy and diabetic participants (Fig. 2).

L-carnitine has been reported to increase acetyl-CoA provision for fatty acid synthesis in the liver and for fatty acid and acetylcholine production in the brain (3,16), apparently through activation of the carnitine acetyltransferase pathway (3,16). Lack of an t-carnitine effect on platelet acetyl-CoA in the absence of glucose indicates that only acetyl groups synthesized in the PDH reaction are available for carnitine acetyltransferase-dependent transport through the mitochondrial membrane (Table 3). Moreover, the absence of or weak stimulatory effects of t-carnitine on acetyl-CoA content and distribution as well as on the functional indicators of platelets from the healthy group indicate that carnitine acetyltransferase-mediated transport is relatively slow under physiologic conditions (Figs. 3 and 4; Tables 4 and 5). In contrast, the marked increases in total and cytoplasmic acetyl-CoA content induced by t-carnitine in platelets from the diabetic group indicate that substrate flow through the carnitine acetyltransferase pathway was markedly increased by chronic hyperglycemia (Table 3; Figs. 3 and 4). The mechanism of this activation remains obscure because the activity of carnitine acetyltransferase in platelets from the diabetic group was only 20% higher, whereas the carnitine-evoked increase in acetyl-CoA was more than 4-fold higher than in platelets from the healthy group (Tables 2 and 3).

Nevertheless, the activation of resting platelets by L-carnitine and thrombin, ADP- or collagen-evoked platelet aggregation, and MDA synthesis in platelets from the diabetic patients led us to conclude that these phenomena are caused by an increased supply of acetyl-CoA to the cytoplasm (Fig. 4; Tables 4 and 5). Moreover, these data indicate that the provision of acetyl-CoA to cytoplasm is necessary for excessive platelet aggregation irrespective of the triggering mechanism (Table 4).

Activation by thrombin of platelets from diabetic patients led to the total elimination of t-carnitine-evoked increases in cytoplasmic acetyl-CoA (Fig. 5), possibly because of excessive use of this metabolite to support the undue platelet activity taking place under these pathologic conditions (Tables 4 and 5). In addition, the importance of acetyl-CoA for excessive activities of platelets in patients with diabetes is evidenced here by the existence of significant correlations between acetyl-CoA concentrations and MDA synthesis or platelet aggregation (Fig. 6B and Table 6).

In platelets, MDA is synthesized from arachidonic acid in equivalent amounts with thromboxane [A.sub.2] and derived thomboxane [B.sub.2] (25, 30). However, much greater amounts of MDA are formed in peroxidation processes of other platelet lipids (31). Nevertheless, a strong correlation between MDA and thromboxane [B.sub.2] was found in diabetic patients (31). Thus, the diabetes/t-carnitine-evoked increases in MDA synthesis reported here apparently reflect changes in thromboxane [A.sub.2] synthesis taking place under these conditions (Table 5). Therefore, the marked increases in both acetyl-CoA concentrations and MDA synthesis in platelets from the diabetic patients (Tables 3 and 5) as well as the significant correlation between these 2 indicators (Table 6) suggest that surplus acetyl-CoA may trigger excessive platelet activity through stimulation of thromboxane [A.sub.2] synthesis and/or lipid peroxidation (Figs. 4 and 5; Tables 4 and 5) (31).

The lack of evident effects of L-carnitine on platelets from healthy persons and the presence of significant stimulatory effects on cytoplasmic acetyl-CoA amounts and platelet function in platelets from diabetic patients indicate that activation of acetyl-CoA transport to the cytoplasm through the carnitine acetyltransferase pathway plays a principal role in excessive platelet activity in diabetes (Fig. 4; Tables 3, 4, and 5). These data are in accordance with reports on the absence of stimulating effects of propionyl-t-carnitine on platelet-activating factor synthesis and arachidonic acid consumption in healthy individuals (12,13). However, we found no reference data on platelets from patients with diabetes.

The data presented here show a similar increase in MDA synthesis and other platelet markers in resting and thrombin-activated platelets from patients with type 1 and 2 diabetes (Tables 1 and 5), whereas Vericel et al. (32) found activation of resting MDA synthesis only in patients with type 1 diabetes. The reasons for this discrepancy remain unknown. One can also assume that L-carnitine--induced increases in cytoplasmic acetyl-CoA in platelets of diabetic persons (Fig. 5) promote synthesis of platelet-activating factor. However, the available data instead indicate that in resting platelets from healthy individuals, L-carnitine causes slight inhibition of platelet-activating factor synthesis (13), which is consistent with our finding of no significant effects of L-carnitine on platelet function in the resting state (Fig. 4; Tables 4 and 5).

Our results indicate a causative relationship between increased acetyl-CoA and excessive activity of platelets in persons with diabetes (Figs. 2, 4, 5, and 6; Tables 4, 5, and 6). This conclusion is supported by the existence of significant positive correlations between acetyl-CoA content in platelets from diabetic patients and the indicators of their function either under resting conditions or after activation with thrombin (Table 6; Fig. 6). The absence of such relationships from platelets from healthy individuals supports the notion that the supply of acetyl-CoA is not a rate-limiting factor for physiologic platelet functions (Table 6 and Fig. 6). In platelets from diabetic patients, L-carnitine stimulates formation of an additional pool of acetyl-CoA that could easily reach the cytoplasmic compartment and trigger further, proportional increases in platelet activity (Tables 3 and 6; Figs. 4 and 6).

In conclusion, our data suggest that L-carnitine may exert an undesirable effect in persons with diabetes, aggravating excessive platelet activity by increasing the acetyl-CoA supply to their cytoplasmic compartment. On the other hand, the generally beneficial effects of L-carnitine supplementation in diabetes might be attributable to increased turnover and use of free fatty acids, improving the energy balance in insulin-dependent and--independent tissues.

This work was supported by Ministry of Scientific Research and Information Technology Project 3P05B 08223 and Medical University of Gdansk Projects W-78 and St-57.


(1.) Trovati M, Anfossi G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia 1998;41:609-22.

(2.) Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992;41:26-31.

(3.) Bremer J. Carnitine--metabolism and functions. Physiol Rev 1983;63:1420-80.

(4.) Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, et al. The role of ATP-citrate lyase in the metabolic regulation of plasma lipids. Biochem J 1998;334:113-9.

(5.) Sullivan AC, Hamilton JG, Miller ON, Wheatley VR. Inhibition of lipogenesis in rat liver by (-)hydroxycitrate. Arch Biochem Biophys 1972;150:183-90.

(6.) Szutowicz A, Tomaszewicz M, Bielarczyk H. Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Acta Neurobiol Exp 1996;56:323-39.

(7.) Bielarczyk H, Tomaszewicz M, Madziar B, Cwikowska J, Pawelczyk T, Szutowicz A. Relationships between cholinergic phenotype and acetyl-CoA level in hybrid murine neuroblastoma cells of septal origin. J Neurosci Res 2003;73:717-21.

(8.) Sheperd PR, Kahn BB. Glucose transporters and insulin action. N Engl J Med 1999;341:248-57.

(9.) Craik JD, Stewart M, Cheeman CI. GLUT-3 (brain-type) glucose transporter polypeptides in human blood platelets. Thromb Res 1995; 79:461-9.

(10.) Michno A, Skibowska A, Raszeja-Spech A, Cwikowska J, Szutowicz. A. The role of adenosine triphosphate-citrate lyase in metabolism of acetyl-coenzyme A and function of blood platelets in diabetes mellitus. Metabolism 2004;53:66-72.

(11.) Skibowska A, Raszeja-Spech A, Szutowicz. A. Platelet function and acetyl-coenzyme A metabolism in type 1 diabetes mellitus. Clin Chem Lab Med 2003;41:1136-43.

(12.) Pignatelli P, Lenti L, Sanguigni V, Frati G, Simeoni I, Gazzaniga PP, et al. Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress. Am J Physiol Heart Circ Physiol 2003; 283:H41-8.

(13.) Triggiani M, Oriente A, Golino P, Gentile M, Battaglia C, Brevetti G, et al. Inhibition of platelet activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine. Biochem Pharmacol 1999;58:1341-8.

(14.) Ishikura H, Takeyama N, Tanaka T. Effects of 2-tetradecylglycidic acid on rat platelet energy metabolism and aggregation. Biochim Biophys Acta 1992;1128:193-8.

(15.) Willoughby SR, Chirkov YY, Kennedy JA, Murphy GA, Chirkova LP, Horovitz JD. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol 1998; 356:207-13.

(16.) Ricny J, Tucek S, Novakova J. Acetylcarnitine, carnitine and glucose diminish the effect of muscarinic antagonist quinuclidynyl benzilate on striatal acetylcholine content. Brain Res 1992;576: 215-9.

(17.) Alberts AW, Ferguson K, Hennessy S, Vagelos PR. Regulation of lipid synthesis in cultured animal cells. J Biol Chem 1974;249: 5241-9.

(18.) Pawelczyk T, Angielski S. Cooperation of Ca and pH in regulation of the activity of the 2-oxoglutarate dehydrogenase complex and its components from bovine kidney cortex. Acta Biochim Pol 1984;3:289-305.

(19.) Edwards YH, Chase JFA, Edwards MR, Tubss PK. Carnitine acetyltransferase: the question of multiple forms. Eur J Biochem 1974;46:209-15.

(20.) Glock GE, McLean P. Further studies on the properties and assay of glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase in rat liver. Biochem J 1953;55:400-8.

(21.) Wright JA, Maeba P, Sanwall BD. Allosteric regulation of the activity of citrate synthase of Escherichia coli by [alpha]-ketoglutarate. Biochem Biophys Res Commun 1967;29:34-40.

(22.) Kawasaki K, Miyano M, Hirase K, Iwamoto M. Amino acids and peptides. XVIII. Synthetic peptides related to N-terminal portion of fibrin [alpha]-chain and inhibitory effects on fibrinogen/thrombin clotting. Chem Pharm Bull 1993;41:975-7.

(23.) Szutowicz A, Bielarczyk H. Elimination of CoASH interference from acetyl-CoA cycling assay by malefic anhydride. Anal Biochem 1987;164:292-6.

(24.) Bielarczyk H, Szutowicz A. Evidence for the regulatory function of synaptoplasmic acetyl-CoA in acetylcholine synthesis in nerve endings. Biochem J 1989;262:377-80.

(25.) Pense M, Black H, Fuster W, Mest H. An improved malonyl dialdehyde assay for estimation of thromboxane synthetase activity in washed human blood platelets. Prostaglandins 1985;30: 1031-8.

(26.) Bradford M. A rapid sensitive method for the quantitation of microgram quantities of protein using principle of dye protein binding. Anal Biochem 1976;21:248-54.

(27.) Girard J. Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu Rev Nutr 1997;17:325-52.

(28.) lida N, lida R, Takeyama N, Tanaka T. Increased platelet aggregation and fatty acid oxidation in diabetic rats. Biochem Mol Biol Int 1993;30:177-85.

(29.) Holmsen H. Biochemistry and function of platelets. In: Williams WJ, ed. Hematology. New York: McGraw-Hill, 1997:1182-243.

(30.) Wachowicz B, Olas B, Zbikowska HM, Buczynski A. Generation of reactive oxygen species in blood platelets. Platelets 2002;13: 175-82.

(31.) Jain SK, Krueger KS, McVie R, Jaramillo JJ, Palmer M, Smith T. Relationship of blood thromboxane-B2 (TxB2) with lipid peroxides and effect of vitamin E and placebo supplementation on TxB2 and lipid peroxide levels in type 1 diabetic patients. Diabetes Care 1998; 21:1511-6.

(32.) Vericel E, Januel C, Carreras M, Moulin P, Lagarde M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 2004; 53:1046-51.


Chair Clinical Biochemistry, Departments of [1] Laboratory Medicine and [2] Molecular Medicine, Medical University of Gdansk, Gdansk, Poland.

[3] Nonstandard abbreviations: PDH, pyruvate dehydrogenase, ACL, ATP-citrate lyase; Hb [A.sub.1c], hemoglobin Ale; and MDA, malonyl dialdehyde.

* Address correspondence to this author at: Department of Laboratory Medicine, Medical University of Gdansk, Debinki 7, 80-211 Gdansk, Poland. Fax 48-58-349-2784; e-mail

Received March 1, 2005; accepted June 7, 2005.

Previously published online at DOI: 10.1373/clinchem.2005.050328
Table 1. Demographic and basic laboratory data
of healthy and diabetic participants. (a)

 Type 1 Type 2
 Controls diabetes diabetes

No. of individuals 29 12 20
Men/Women 13/16 6/6 10/8
Duration of the 11.4 (1.1) 14.5 (0.9)
 disease, years
Age, years 47.4 (2.1) 39.7 (2.6) (b) 57.6 (2.4) (b)
Glucose, mg/L 950 (30) 2130 (200) (c) 1910 (90) (c)
Fructosamine, 245 (5) 369 (15) (c) 379 (15) (c)
Hb [A.sub.1c], % 5.1 (0.1) 9.0 (0.4) (c) 9.1 (0.3) (c)
PLTs, (d) [10.sup.3]/L 256 (8) 274 (26) 245 (12)
MPV, fL 8.8 (0.2) 9.1 (0.2) 9.1 (0.2)
Cholesterol, mg/L 1960 (100) 1970 (90) 2300 (100) (b)
Triglycerides, mg/L 1060 (60) 1110 (80) 1800 (100) (c,e)

(a) All data are the means (SE) except for the
number of participants and sex.

(b,c) Significantly different from healthy persons
(unpaired Student t-test): (b) P < 0.05; (c) P < 0.001.

(d) PLTs, platelets; MPV, mean platelet volume.

(e) Significantly different from patients with
type 1 diabetes, P < 0.001.

Table 2. Activities of selected enzymes involved in acetyl-CoA
metabolism in blood platelets from healthy and diabetic persons. (a)

 Specific activity, nmol x [min
 .sup.-1] x [(mg protein).sup.-1]

 Healthy Diabetic
 Enzyme persons patients

Glucose-6-phosphate dehydrogenase 70.7 (3.6) 82.9 (3.7) (b)
 No. of observations 21 20
Carnitine acetyltransferase 14.7 (0.5) 17.7 (0.7) (c)
 No. of observations 25 24
2-Oxoglutarate dehydrogenase 2.76 (0.10) 3.77 (0.19) (c)
 No. of observations 14 14
Fatty acid synthetase 1.42 (0.10) 2.29 (0.20) (c)
 No. of observations 14 12
Citrate synthase 39.3 (4.8) 44.8 (3.3)
 No. of observations 22 20

(a) Data are the means (SE) from number of observations given.

(b,c) Significantly different from healthy group (unpaired
Student t-test); (b) P < 0.05; (c) P < 0.001.

Table 3. Effect of L-carnitine on acetyl-CoA concentrations
in resting platelets incubated in medium without glucose or
containing 2.5 mmol/L glucose. (a)

 Acetyl-CoA content, pmol/mg protein

 Healthy Diabetic
 group group

Medium with no glucose
 Control 11.0 (2.1) 17.6 (2.3) (b)
 2.5 mmol/L L-carnitine 13.4 (1.1) 19.1 (1.7) (b)
Medium containing 2.5
 mmol/L glucose
 Control 16.1 (0.9) 25.5 (1.1) (c)
 2.5 mmol/L L-carnitine 21.4 (1.4) (c) 43.1 (2.8) (c,d)

(a) Data are the means (SE) from 17 (no glucose) and 32 (2.5
mmol/L glucose) duplicate observations.

(b,c) Significantly different from healthy group (unpaired
Student t-test): (b) P <0.01; (c) P < 0.001.

(d) Significantly different from respective controls (paired
Student t-test): (d) P <0.0001.

Table 4. Effect of L-carnitine on resting antagonist-evoked
aggregation of blood platelets incubated in medium
containing 2.5 mmol/L glucose. (a)

 Aggregation, %

 Healthy Diabetic
 Additions group group

Resting aggregation
 Control 5.7 (0.2) 9.1 (0.4) (b)
 2.5 mmol/L L-carnitine 7.7 (0.3) (d) 14.6 (0.8) (b,d)
Thrombin (0.1 U/mL)-evoked
 Control 70.9 (0.8) 80.8 (0.7) (b)
 2.5 mmol/L L-carnitine 74.4 (1.0) (d) 89.4 (0.8) (b,d)
ADP (0.01 mmol/L)-evoked
 Control 56.8 (2.4) 65.7 (2.4) (c)
 2.5 mmol/L L-carnitine 57.5 (2.3) 72.3 (2.1) (b,e)
Collagen (0.05 mmol/L)-evoked
 Control 64.3 (1.6) 72.3 (1.7) (c)
 2.5 mmol/L L-carnitine 65.7 (2.9) 82.5 (1.3) (b,d)

(a) Data are the means (SE) from 30 (thrombin) and 6 (ADP and
collagen) duplicate observations.

(b,c) Significantly different from healthy persons (unpaired
Student t-test): (b) P <0.001; (c) P < 0.05.

(d,e) Significantly different from respective controls (paired
Student t-test): (d) P <0.001; (e) P < 0.05.

Table 5. Effect of L-carnitine on resting and thrombin-
evoked MDA synthesis in blood platelets incubated in
medium containing 2.5 mmol/L glucose. (a)

 MDA synthesis,
 nmol x [(10 min).sup.-1] x
 [(mg protein).sup.-1]

Additions Healthy group Diabetic group
Resting MDA synthesis
 Control 0.40 (0.02) 0.64 (0.03) (b)
 2.5 mmol/L L-carnitine 0.50 (0.02) (c) 1.03 (0.05) (b,c)
Thrombin (0.1 U/mL)-evoked MDA
 Control 1.67 (0.05) 2.89 (0.08) (b)
 2.5 mmol/L L-carnitine 1.85 (0.08) (c) 3.78 (0.09) (b,c)

(a) Data are the means (SE) from 30 duplicate observations.

(b) Significantly different from healthy group (unpaired Student
t-test), P < 0.001.

(c) Significantly different from respective controls (paired
Student t-test), P < 0.001.

Table 6. Correlations between acetyl-CoA content and
blood platelet function in healthy and diabetic persons. (a)

 Correlation (r)

 2.5 mmol/L
 No L-carnitine L-carnitine

Healthy group
 Spontaneous MDA synthesis -0.03 0.28
 Thrombin-induced MDA synthesis -0.19 -0.07
 Spontaneous aggregation 0.08 0.41 (b)
 Thrombin-induced aggregation 0.41 (b) 0.29

Diabetic group
 Spontaneous MDA synthesis 0.60 (c) 0.70 (d)
 Thrombin-induced MDA synthesis 0.56 (c) 0.64 (d)
 Spontaneous aggregation 0.38 0.61 (d)
 Thrombin-induced aggregation 0.70 (d) 0.71 (d)

(a) For numbers of observations and units, see Tables 4 and 5.

(b-d) Significances of correlation: (b) P < 0.05; (c) P < 0.01;
(d) P < 0.001.
COPYRIGHT 2005 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Endocrinology and Metabolism
Author:Michno, Anna; Raszeja-Specht, Anna; Jankowska-Kulawy, Agnieszka; Pawelczyk, Tadeusz; Szutowicz, Andr
Publication:Clinical Chemistry
Date:Sep 1, 2005
Previous Article:Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and...
Next Article:Routine isotope-dilution liquid chromatography--tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins...

Related Articles
L-Carnitine (L-Carnipuire[R]). (Nutraceuticals Research).
Cloning and expression of three AMP-forming acetyl-Co synthetase genes from Sulfolobus solfataricus. (South Carolina Junior Academy Of Sciences...
L-carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly.
Restoring leptin sensitivity in brain cures severe diabetes, doubles activity levels in mice.
The effects of feeding triacylglycerols on milk fat composition, lipogenesis and polymer-protomer transition of acetyl-CoA carboxylase in rat mammary...
Increased C3-carnitine in a healthy premature infant.
Untargeted metabolomic analysis hits the target.
Tandem mass spectrometric determination of malonylcarnitine: diagnosis and neonatal screening of malonyl-CoA decarboxylase deficiency.
L-carnitine for exercise and weight management.

Terms of use | Copyright © 2015 Farlex, Inc. | Feedback | For webmasters